Skip to main content

Global Public Health Portfolio

The World Health Organization, Coalition for Epidemic Preparedness, and the National Institute of Allergy and Infectious Diseases of the United States National Institute of Health have published lists of their priority pathogens, including emerging threats and neglected diseases. 

The mRNA Access program will offer researchers use of Moderna’s mRNA technology to target these identified priority pathogens to accelerate the development of medicines to prevent these diseases.

Interested in mRNA Access?

Partner with us to bring this global health initiative to life.

By submitting your information, you agree to Moderna’s Terms and Conditions. You also acknowledge that your information will be processed in accordance with Moderna’s Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Services apply.